Peptidal Therapeutics

Peptidal Therapeutics is a biotechnology company pioneering peptide-based therapeutics for central nervous system (CNS) disease and injury. We focus on some of medicine’s most urgent unmet needs — blinding visual diseases and devastating neurological conditions including glaucoma, stroke, and traumatic brain injury.

Our pipeline reflects a commitment to translating peptide biology into treatments that can genuinely change the lives of patients living with vision loss and neurological injury.

Contact:
Don Watts (Executive Advisor): Don.watts@peptidaltherapeutics.com

Paulo Koeberle (CSO): Paulo.koeberle@utoronto.ca